Martina Ott joined Immatics in 2014. She is responsible for designing and leading organizational development initiatives, with the goal to promote and maintain an operational excellence organization actively living the concept of structured continuous process improvement and to ensure sustainable talent development.
Manipulating the immune system to fight diseases has been the focus of Martina’s career. Before joining Immatics, she investigated the effects of a novel immunomodulator developed by Teva Pharmaceuticals to treat multiple sclerosis. As part of Immatics’ Target Research Department, Martina was involved in target validation for several internal and collaboration projects and led the Target Validation Unit until July 2021. In her current role, Martina works on key R&D and general organizational development projects to support Immatics' continuous growth and to successfully manage associated change processes.
Martina Ott holds a Diploma in Molecular Medicine from the University of Erlangen-Nuremberg and a Ph.D. in Molecular Medicine from the University of Goettingen.